FDA Warns Tex Peptides Over Unapproved Drug Claims

The FDA has issued a warning letter to TXP Innovations LLC, doing business as Tex Peptides, following a review of the company's website. According to the FDA warning letter, the agency flagged product listings for items labeled "Semaglutide," "Tirzepatide," "Retatrutide," SS-31, Tesamorelin, PT-141, and bacteriostatic water as unapproved new drugs under the Federal Food, Drug, and Cosmetic Act.

The letter points to specific marketing language on the company's site as evidence of drug like intended use. Pages for the semaglutide and tirzepatide listings described effects on insulin secretion, glucagon suppression, and weight management, framing the peptides for conditions like type 2 diabetes and obesity. The retatrutide page claimed the compound could offer "superior outcomes" compared to other agents, while the SS-31 page described mitochondrial and antioxidant benefits. None of these products carry FDA approval for the uses described, and the agency noted that injectable products carry particular risk because they bypass the body's normal defenses against contamination.

This is a compliance action, not a safety study, and it does not evaluate whether any of these peptides work as researchers hope. It is a reminder that research use marketing has boundaries, and that vendors making disease related claims can draw direct FDA scrutiny.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.